Evaluation of Safety and Efficacy of Xeloda in Metastatic Colorectal Carcinoma
N/A
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Both
Colorectal Cancer
Both
Colorectal Cancer
Trial Information
Evaluation of Safety and Efficacy of Xeloda in Metastatic Colorectal Carcinoma
Inclusion Criteria:
- Adult patients, >/= 18 years of age
- Metastatic colorectal cancer
- Receiving Xeloda according to registered indication
Exclusion Criteria:
- Patients who are not eligible for Xeloda treatment according to the Summary of
Product Characteristics
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Safety: Incidence of adverse events
Outcome Time Frame:
approximately 3 years
Safety Issue:
No
Principal Investigator
Clinical Trials
Investigator Role:
Study Director
Investigator Affiliation:
Hoffmann-La Roche
Authority:
Serbia: Medicines and Medical Devices Agency
Study ID:
ML22585
NCT ID:
NCT01697462
Start Date:
July 2009
Completion Date:
July 2013
Related Keywords:
- Colorectal Cancer
- Colorectal Neoplasms
Name | Location |
|---|
